BLUE bluebird bio Inc.

135.75
+3.1  (+2%)
Previous Close 132.65
Open 133.27
Price To Book 4.22
Market Cap 7,482,982,002
Shares 55,123,256
Volume 558,068
Short Ratio
Av. Daily Volume 558,176

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated in 2019.
LentiGlobin - HGB-210
Sickle Cell Disease (SCD)
Phase 3 data presented at EHA June 14, 2019. 5/11 patients had stopped transfusions for at least three months and had Hb levels of 10.2–13.6 g/dL
LentiGlobin - HGB-212 Northstar-3
TDT and the β0/β0genotype
Phase 2 data due by the end of 2019.
bb2121 - KarMMa
Relapsed/refractory multiple myeloma
Phase 3 updated data due at EHA June 2019 noted 4/5 patients achieved transfusion independence.
LentiGlobin - HGB-207 Northstar-2
non-β0/β0 transfusion-dependent thalassemia (TDT)
Phase 2/3 updated data released September 5, 2018.
Lenti-D - Starbeam
Childhood cerebral adrenoleukodystrophy (CCALD)
Updated data due at EHA June 14, 2019 noted 3.8 years of transfusion independence in patients who do not have a β0/β0 genotype.
LentiGlobin - HGB-204
β-Thalassemia
Phase 1/2 updated data due at EHA June 16, 2019.
LentiGlobin - HGB-206
Sickle disease
Phase 1 data due by the end of 2019.
bb21217
Multiple Myeloma

Latest News

  1. Biotech investors Wellington, RA Capital’s new funds top $700 million
  2. JP Morgan: 2 Gene Therapy Stocks to Buy Now
  3. 5 Immunotherapy Stocks to Keep a Close Eye On
  4. Is bluebird bio a Buy?
  5. Marshall Wace’s Return, AUM, and Holdings (Part II)
  6. Where Will bluebird bio Be in 1 Year?
  7. Why This Biotech's Approved Gene Therapy Won't Launch Until 2020
  8. See what the IHS Markit Score report has to say about bluebird bio Inc.
  9. Is bluebird bio Inc (BLUE) A Good Stock To Buy?
  10. Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?
  11. Bluebird Bio’s Gene Therapy Is $1.8 Million Per Patient. The Stock Is Falling.
  12. Bluebird prices gene therapy in Europe at $1.8M over 5 years
  13. bluebird bio Presents New Data for LentiGlobin® Gene Therapy for Sickle Cell Disease (SCD) at 24th European Hematology Association (EHA) Congress
  14. bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) at 24th European Hematology Association (EHA) Congress
  15. Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license
  16. bluebird bio (NASDAQ:BLUE) Shareholders Have Enjoyed An Impressive 223% Share Price Gain
  17. bluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® (autologous CD34+ cells encoding βA-T87Q-globin gene) Approval